Clinical trial
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in…
NCT00444587 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00444587 |
|---|---|
| Title | A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. |
| Official title | A Multicenter Phase II Trial of Trastuzumab (Herceptin) Continuation in Combination With 2nd-line Chemotherapies After Progression on a 1st-line Chemotherapy Combined With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer (Treatment Beyond Progression, TBP) |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Second line chemotherapy, trastuzumab [Herceptin] |
| Enrollment | 114 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Mar 8, 2007 |
| Last update posted | Jun 21, 2016 |
| Countries | Bulgaria, Estonia, Hungary, Israel, Lithuania, North Macedonia, Slovakia, Turkey (Türkiye) |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: